Medicaid Payments for Multiuse Vials of Herceptin
Previous OIG audits of Herceptin, a drug used to treat breast cancer, have shown provider noncompliance with Medicare billing requirements. Similar issues may occur in Medicaid. We will review States' claims for the Federal share of Medicaid payments for Herceptin to determine whether providers properly billed the States for the drug. We will determine whether providers' claims to States were complete and accurate and were billed in accordance with the regulations of the selected States.
|Announced or Revised
|Expected Issue Date (FY)
|Centers for Medicare & Medicaid Services
|Medicaid Payments for Multiuse Vials of Herceptin
|Office of Audit Services